Ranolazine

Drug Name: Ranolazine
Company: Gilead
Website: http://www.gilead.com
Drug Type: Small Molecule
Conditions: ALS, Chronic Angina (Chest Pain)
Mechanism Type: Neuronal hyperexcitability
Mechanism: Ranolazine is a sodium channel blocker that may reduce neuronal hyperexcitability by reducing sodium ion influx (the persistent sodium current).
U.S. Status for ALS: Phase II

References:
[1] Safety and Efficacy of Ranolazine for the Treatment of Amyotrophic Lateral Sclerosis Clinicaltrials.gov, 19 Jun 2018. Accessed 9 Aug 2018 from https://www.clinicaltrials.gov/ct2/show/NCT03272503.
[2] Study Design and Preliminary Results of Safety and Efficacy of Ranolazine for the Treatment of Amyotrophic Lateral Sclerosis Hamasaki A et al.,
Neurology. 2018 Apr 25;90 (15 Supplement).
[3] Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Antzelevitch C et al.,
Circulation. 2004 Aug 24;110(8):904-10.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail